Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.99B | 30.08B | 30.24B | 30.27B | 29.58B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.99B | 30.08B | 30.24B | 30.27B | 29.58B |
| Cost of Revenue | 10.50B | 10.32B | 10.48B | 10.32B | 10.04B |
| Gross Profit | 19.49B | 19.76B | 19.77B | 19.95B | 19.54B |
| SG&A Expenses | 7.29B | 7.25B | 7.23B | 7.27B | 7.22B |
| Depreciation & Amortization | 3.61B | 3.60B | 3.60B | 3.63B | 3.60B |
| Other Operating Expenses | 103.72M | 404.46M | 288.59M | -175.43M | 352.57M |
| Total Operating Expenses | 26.21B | 26.37B | 26.29B | 25.89B | 26.15B |
| Operating Income | 3.78B | 3.71B | 3.95B | 4.38B | 3.43B |
| Income Before Tax | 1.32B | 1.15B | 1.53B | 1.77B | 306.89M |
| Income Tax Expenses | 355.19M | 437.74M | 165.33M | -152.99M | -668.77M |
| Earnings from Continuing Operations | 959.94 | 710.88 | 1.37K | 1.93K | 975.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.34M | -1.41M | -1.20M | -1.14M | -1.14M |
| Net Income | 958.61M | 709.46M | 1.37B | 1.93B | 974.51M |
| EBIT | 3.78B | 3.71B | 3.95B | 4.38B | 3.43B |
| EBITDA | 8.20B | 8.11B | 8.40B | 8.88B | 7.89B |
| EPS Basic | 0.61 | 0.45 | 0.87 | 1.22 | 0.62 |
| Normalized Basic EPS | 1.12 | 1.11 | 1.22 | 1.37 | 0.99 |
| EPS Diluted | 0.60 | 0.44 | 0.85 | 1.21 | 0.62 |
| Normalized Diluted EPS | 1.10 | 1.09 | 1.20 | 1.36 | 0.99 |
| Average Basic Shares Outstanding | 6.31B | 6.32B | 6.31B | 6.29B | 6.27B |
| Average Diluted Shares Outstanding | 6.36B | 6.37B | 6.35B | 6.34B | 6.29B |
| Dividend Per Share | 1.30 | 1.30 | 1.29 | 1.29 | 1.28 |
| Payout Ratio | 217.56% | 277.06% | 143.72% | 101.03% | 199.79% |